Confirm
Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD
Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023
-- Conference Call Today at 4:30 p.m. (ET) --
PR Newswire
ROCKVILLE, Md., May 5, 2021
ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2021.